Revenue by Business Segment:

1. Vaccines: 70%
2. Contract Development and Manufacturing (CDMO): 20%
3. Research and Development: 10%

TOP 3 Markets:

1. South Korea: 40%
2. USA: 30%
3. Europe: 20%

SK bioscience Co., Ltd. generates the majority of its revenue from the vaccine business, which accounts for approximately 70% of total revenue. This includes both the production and distribution of vaccines for various diseases.

The South Korean market is the largest single market for the company, followed by the USA and Europe. These markets are crucial for the growth of SK bioscience as they offer both high demand and strategic partnerships.

Production sites of SK bioscience Co., Ltd.:

1. Andong L-Haus Biopharmaceutical Complex, South Korea

SK bioscience Co., Ltd. mainly produces its products in South Korea, particularly at the Andong L-Haus Biopharmaceutical Complex. This state-of-the-art facility is known for its advanced technologies and high production capacities, enabling the company to serve both domestic and international markets.

The company specializes in vaccine manufacturing and utilizes its production facilities to develop and produce a variety of biopharmaceutical products. The strategic location in South Korea allows SK bioscience to benefit from proximity to key markets in Asia while maintaining global partnerships.

Focus on Vaccine Development and Production
Expansion of Global Presence
Investments in Research and Development

SK bioscience Co., Ltd. is strongly focused on the development and production of vaccines to secure future growth. In recent years, the company has significantly expanded its capacities in this area to be able to respond to both pandemic and endemic health threats.

Another strategic focus is on expanding global presence. SK bioscience aims to export its products to new markets and strengthen partnerships with international organizations and governments to increase the worldwide availability of their vaccines.

Furthermore, the company is continuously investing in research and development to develop innovative solutions in the field of biotechnology. These investments are intended not only to expand the existing product range but also to increase the company's competitiveness in the global market.

Main raw materials: Vaccine components, Biopharmaceutical materials

Countries of origin: USA, Germany, China

SK bioscience Co., Ltd. imports a variety of raw materials necessary for the production of vaccines and biopharmaceutical products. The main raw materials include specific vaccine components and biopharmaceutical materials.

The USA and Germany are significant suppliers of high-quality biopharmaceutical materials essential for research, development, and production of vaccines. China also supplies important chemical components used in manufacturing.

These international supply chains are crucial for maintaining production capacities and ensuring product quality for SK bioscience.

Market share in the vaccine sector: 8% (estimated for 2026)
R&D investments: 12% of revenue (2025)
Partnerships: Collaboration with global pharmaceutical companies such as GlaxoSmithKline and AstraZeneca

SK bioscience Co., Ltd. has established itself as a significant player in the global vaccine market, particularly through its advanced R&D investments, which account for approximately 12% of revenue. These investments enable the company to develop innovative vaccines and continuously expand its product pipeline.

Another competitive advantage arises from strategic partnerships with major pharmaceutical companies such as GlaxoSmithKline and AstraZeneca. These collaborations not only strengthen SK bioscience's market position but also enhance their access to new technologies and markets.

The estimated 8% market share in the vaccine sector indicates that the company holds a solid position, but operates in a highly competitive market. To further enhance its competitive advantage, it will be crucial to maintain innovation capabilities and strengthen global presence.

Institutional Investor Share: 45% (estimated for 2026)

Insider Buys/Sells: No significant transactions in the last 12 months

The institutional investor share in SK bioscience Co., Ltd. is estimated to be around 45%. This indicates a strong interest from institutional investors, suggesting confidence in the company's long-term strategy and growth potential.

Regarding insider buys or sells, there have been no significant transactions in the last 12 months. This could indicate that the management and other insiders are satisfied with the current valuation of the company or do not expect any significant changes in the company's strategy or performance.

Market share of SK bioscience Co., Ltd.: 8% (estimated, 2026)

Top competitors and their market shares:

1. Pfizer Inc.: 20%
2. Moderna, Inc.: 18%
3. Johnson & Johnson: 15%
4. AstraZeneca: 12%
5. Sanofi: 10%
6. SK bioscience Co., Ltd.: 8%
7. GlaxoSmithKline plc: 7%
8. Novavax, Inc.: 5%
9. BioNTech SE: 3%
10. Sinovac Biotech Ltd.: 2%

Moat of SK bioscience Co., Ltd.:

SK bioscience has made a name for itself through its innovation and development of vaccines against novel viruses. The company's moat lies in its strong R&D department and its ability to quickly respond to new health crises. This has helped the company secure a respectable market share.

However, compared to larger competitors like Pfizer and Moderna, which have more extensive financial resources and a broader product range, the moat of SK bioscience is less pronounced. These companies have established distribution networks and brand recognition that are hard to surpass.

In summary, SK bioscience has a solid but not insurmountable moat. The competition has significant advantages in many areas, especially in global reach and financial strength.

Revenue Growth: 18% (2025) Research and Development Ratio: 12% of revenue (2025)

SK bioscience Co., Ltd. recorded a revenue growth of 18% in 2025, driven by strong demand for their vaccines and health solutions. The company continues to invest heavily in research and development, with a ratio of 12% of revenue, indicating a long-term innovation strategy.

The strategic focus on expanding the product pipeline and entering new markets could further strengthen the company in the coming years. Additionally, SK bioscience benefits from partnerships and collaborations with international health organizations, enhancing global presence and market opportunities.

Overall, the revenue growth and high investment in research and development suggest that SK bioscience is well positioned to capitalize on future market opportunities. This could make the stock an attractive investment for long-term investors looking to capitalize on growth in the healthcare sector.

Dividend payment: No dividend (2026)

SK bioscience Co.,Ltd. has not paid any dividends in recent years. The company focuses on reinvesting in research and development as well as expanding into new markets, especially in the field of vaccine production.

The decision not to pay a dividend reflects the strategic focus on long-term growth. Investors should therefore focus more on capital gains rather than dividend income.